Table 1 MSCs in clinical trials treating liver fibrosis
From: Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis
Cell source | Delivery route | No. of cells | Patient population | No. of patients | Follow-up period | Efficacy | Limitations | Reference |
|---|---|---|---|---|---|---|---|---|
UC-MSCs | Intravenous | 5 × 105/kg, three times | Chronic hepatitis B | 30 treatment, 15 control | 12 months | Improvement of liver function and MELD score; reduced ascites | No track of the infused UC-MSCs and the histological evidence in the studied patients | [22] |
UC-MSCs | Intravenous | 5 × 105/kg, three times | Primary biliary cirrhosis | 7 treatment | 48 weeks | Decrease in serum ALP and γ-GGT; alleviation of fatigue and pruritus | No track of the infused UC-MSCs and histological evidence alterations in the studied patients; less detailed follow-up time points | [23] |
BM-MSCs | Intravenous infusion | 1 × 107/kg | Liver cirrhosis due to hepatitis C virus | 15 treatment,10 control | 6 months | Improvement in the frequency of encephalopathy, jaundice, ascites, bleeding tendency, and lower limb edema | Less detailed follow-up time points | [24] |
Autologous BM-MSCs | Hepatic artery | 0.75 ± 0.50× 106/patient | Hepatitis B virus cirrhosis | 27 treatment,29 control | 24 weeks | Significant improvement in liver function | During follow-up, patients were lost about 1/3 | [25] |
Autologous BM-MSCs | Peripheral vein | 1 × 106/kg | End-stage liver disease due to hepatitis C virus | 20 treatment,20 control | 6 months | Significant improvement in liver function | No histological evidence; less detailed follow-up time points | [26] |